调节免疫中成药与系统性红斑狼疮感染
摘要
背景
系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种自身免疫性疾病。该病是以产生多种自身抗体,并由免疫反应介导炎症为特征的累及多器官、多系统的弥漫性结缔组织病,病情轻重不一。近20年来,环磷酰胺(CTX)、糖皮质激素冲击疗法作为重型SLE诱导缓解的常用疗法。狼疮危象常常需要CTX、大剂量甲基泼尼松龙或加用大剂量免疫球蛋白冲击治疗。虽然近年来SLE的治疗方面有许多新进展,但国内外仍以糖皮质激素加免疫抑制剂为主。它们常能有效控制疾病活动、改善病情,有效提高了SLE患者的存活率。但是大剂量免疫抑制剂和糖皮质激素的副作用及并发症也不容忽视。许多临床研究表明,大剂量CTX、甲基泼尼松龙冲击治疗后出现诸如带状疱疹、肺炎、泌尿系感染及脑炎等感染,可见于20%以上的患者。特别是经CTX或甲基泼尼松龙冲击治疗后的患者免疫力低下,并发感染的几率大大增加,已成为SLE患者死亡的主要原因之一。
近年来,中医中药在SLE治疗中的作用逐渐引起人们的重视。中医古代文献中虽没有以系统性红斑狼疮为病名的论述,但对其相似或相关论述甚广,历经数千年之积淀,对其论述涉及本病诸多方面。根据其临床症状表现,不少中医学者将它归属于“蝴蝶斑”、“阴阳毒”、“日晒疮”等范畴。目前国内中医学家对此病证认识颇多,大都认为该病的基础是先天禀赋不足。所以补其不足在系统性红斑狼疮中的研究中占重要地位。代表药物如六味地黄丸,此外百令胶囊、白芍总苷等也被常用于SLE的辅助治疗。
六味地黄丸是阴中求阳的代表方,具有滋阴补肾的作用。方中由熟地、丹皮、泽泻、山茱萸、山药、茯苓六味药组成。方中用熟地滋肾填精为主,辅以山茱萸养肝肾而涩精,山药补脾肾而固精又配茯苓淡渗脾湿以助山药益脾,茯苓渗水利湿,使浊水下泻,排出外体,泽泻清泄肾火,并防熟地之滋腻,丹皮清泄肝火,凉血散瘀,除骨蒸之热,并制山茱萸之湿。此方历经数百年医家运用其疗效确切,组方严谨合理,成为滋补肾阴的代表方。现代药理研究证实：六味地黄汤能提高模型动物的白细胞介素(IL)-2活性,IL-2具有促进并维持T淋巴细胞在体内外的生长,参与B淋巴细胞抗体产生,本方还能增强红细胞的免疫功能,方中熟地黄有兴奋或调节肾上腺皮质轴功能,拮抗外源性激素对垂体-肾上腺皮质的抑制作用,延缓肝脏对皮质激素的分解,使血中皮质激素升高。六味地黄方不是单纯的免疫促进剂或免疫抑制剂,而是通过调节机体免疫平衡而发挥作用。
百令胶囊主要成分为人工虫草菌丝体干粉,与天然虫草效果基本一致,具有补肺肾,益精气的功效。现代药理研究显示百令胶囊具有有抗氧化,提高机体细胞免疫力,升高机体白细胞,调节血脂,抗炎等作用,能减轻长期应用糖皮质激素引起的蛋白质分解增加、提高抗感染能力；且对机体免疫系统具有双向调节的功能,既可减轻免疫抑制药的毒副作用,又协同其他免疫抑制药发挥作用。综上百令胶囊具有一定的抗炎及调节免疫作用而不会引起激素样副作用。
百令胶囊和六味地黄丸联合应用对于减少因免疫制剂和激素治疗SLE所致的副作用的研究报道较少,尤其是对SLE并发感染的干预作用研究更少。在过去几年的临床实践中,我们尝试用六味地黄丸联合百令胶囊辅助治疗SLE患者,结果显示,可以有效减低SLE患者感染的几率并能降低感染程度；从而提高临床疗效,降低病死率。为此,特做此相关研究。
目的
1.观察系统性红斑狼疮(SLE)患者并发感染的危险因素,并通过两组治疗后伴发的感染情况,观察中成药(百令胶囊及六味地黄丸)对应用免疫抑制和糖皮质激素治疗的SLE患者的干预作用,从而探寻减少SLE伴发感染的治疗方案,寻找有效且相对安全的治疗方法。
2.观察两组治疗前后的IL-2表达水平,推断调节免疫中成药减少SLE感染在细胞免疫方面的可能机制。
方法
1.分析SLE患者出现感染的危险因素：回顾研究我院和九江学院附属医院风湿科2009年1月1日-2012年1月1日收治的SLE患者82例,以性别、年龄、体质量、病程,血白细胞、血浆白蛋白水平,IL-2、C3、CRP数值,免疫抑制剂及激素应用情况为自变量,观察患者的感染发生率,以及感染发生率与这些指标之间的相关性。本研究中感染包括细菌感染、病毒感染、真菌感染；感染涉及呼吸系统、泌尿系统、皮肤和软组织、中枢神经系统及血液系统等。
2.观察两组的临床疗效及两组感染情况：
2.1研究对象：
回顾性研究2009年1月1日～2012年1月1日伴有肾脏受累和或肺间质性病变的SLE患者61例(均来自规范治疗并定期复诊的患者,入选病例首诊时经常规检测并未合并感染)随机分成两组。中西医结合治疗组31例,男性4例,女性27例；年龄13-65岁,病程平均36.2月。西药对照组30例,其中男性2例,女性28例；年龄14-63岁,病程平均35.8月。两组患者在性别、年龄、病程、病情等方面经检验差异无统计学意义。
2.2给药方法：
对照组：对照组采用糖皮质激素加环磷酰胺进行治疗。A、糖皮质激素：泼尼松lmg/kg/d通常晨起1次服用,待患者病情稳定后2周或疗程8周内,以每2周减10%的速度缓慢减量,减至泼尼松0.5mg/kg/d,治疗的激素剂量尽量小至泼尼松10mg/d。在减药过程中,如果病情不稳定,可暂时维持原剂量不变。B、环磷酰胺：前半年每月一次,稳定后改为每三月一次(用量16-20mg/kg加入生理盐水250m1中静脉滴注,一般每天0.4-0.6g,连用两天)。对有病情严重者,可以使用较大剂量(泼尼松≥2mg/kg/d)甚至甲基泼尼松龙冲击治疗,甲基泼尼松龙可用至500～1000mg,每天1次,加入5%葡萄糖慢静脉滴注1～2小时,连续3天为1疗程,疗程间隔期5-30天,间隔期和冲击后需口服泼尼松1mg/kg/d-2mg/kg/d,疗程和间隔期长短视具体病情而定。治疗组：在对照组基础上加用六味地黄丸(8丸,每日三次)及百令胶囊(1.0g,每日三次)。
2.3观察指标：通过SLEDAI评分观察病情；测定血常规、尿常规,ESR, CRP, C3、C4,IG,免疫荧光抗核抗体(ANA),抗ds-DNA抗体,肝肾功能等变化,比较两种疗法的治疗效果和伴发感染情况(肺部感染、泌尿系感染、中枢神经系统感染等)。两组疗程均为18个月,分别在治疗6、12、18个月后评估患者病情。
3.百令胶囊联合六味地黄丸对SLE患者血清IL-2水平的影响
分别在两组患者初诊及治疗后6、12、18个月后,常规分离患者外周血清3m1,并将其置于-80。C下保存备用。按照人IL-2ELISA检测试剂盒中所提供的检测操作说明,检测相应患者血清中IL-2水平。
结果
1.结果显示SLE患者伴发感染的易感因素主要有补体缺陷(补体C3),糖皮质激素冲击、长期免疫抑制剂使用,病情活动性,累及系统和脏器的数量,住院时间相关(P<0.05)；与性别、年龄、体质量、病程无明显相关(P>0.05)；SLE合并感染以呼吸道部感染和泌尿系感染为主；病原菌以革兰阴性菌为主,条件致病菌相对较多。
2.临床研究得出：治疗组总有效率(83.8%)高于对照组(73.3%),其差异有统计学意义。治疗6个月后治疗组感染率9.67%,对照组16.67%；治疗12个月后治疗组感染率12.90%；对照组20.68%；18个月后感染率,治疗组16.67%,对照组为25%,治疗组感染率明显低于对照组,经统计学分析有显著差异(P<0.05)。
3.治疗组患者IL-2水平显著高于对照组,治疗6个月、12个月、18个月后,治疗组白介素2水平分别为6.97±1.32pg/ml,7.26±1.25pg/ml；7.54±1.24pg/ml;对照组为5.29±1.26pg/ml；5.42±0.99pg/ml；5.63±1.15pg/ml.经统计学分析两组数据有差异(P<0.05)。
结论
1.对照组(单纯免疫抑制治疗系统性红斑狼疮组),患者易伴发感染,这也是导致患者多脏器功能衰竭甚至死亡的重要原因。长期大剂量免疫抑制剂、激素冲击治疗,免疫力低下(血白细胞计数降低、血浆白蛋白水平下降等),C3水平低下、累及的脏器个数,住院时间延长、病情活动性是伴发感染的独立危险因素。
2.百令胶囊联合六味地黄丸可以有效缓解免疫抑制剂和激素治疗系统性红斑狼疮导致的并发症,增加临床疗效,可以减少SLE患者出现感染的几率,减轻感染症状。故可以作为临床医师治疗系统性红斑狼疮的一种有效治疗方案。
3.百令胶囊联合六味地黄丸增加了系统性红斑狼疮患者IL-2的分泌；能减少系统性红斑狼疮并发感染率,可能与增高的IL-2可促进患者本病的病情稳定有关。从侧面说明二者有通过调节免疫作用达到改善肺部、肾脏等脏器的功能状态,提高患者免疫力的作用。
意义
1.本研究主要观察了调节免疫中成药对系统性红斑狼疮患者免疫抑制治疗后并发感染率的影响。目前国内外很少见到相同的研究报告,研究内容新颖,临床实用性强；拓宽了研究视野,为以后深入研究打下了一定基础。
2.本研究检测了系统性红斑狼疮患者的IL-2水平,发现实验组的IL-2水平的增高与该组的感染率下降相平行,从而为通过细胞因子网络调控领域探讨调节免疫中成药作用机理提供了基础；为该类药治疗效果的评判提供了一个有参考价值的范例。
Background
Systemic lupus erythematosus(SLE) is an autoimmune disease. It is a kind of diffuse connective tissue disease characterized by producing a variety of antibodies and immune response mediated inflammation. It related to involvement of several visceral organs. The condition ranges from mild to severe. In recent20years, the cyclophosphamide (CTX) and corticosteroid therapy were used as a classic method for the induction therapy of heavy SLE internationally. Lupus crisis often need combined with CTX, the impact of large dose methylprednisolone and immune globulin or three treatment. At present, there are many new advances in the treatment of SLE. However, the treatment is still dominated by hormone and immunosuppressant at home and abroad. They can effectively control the disease activity, improve the condition and the survival rate of patients with SLE. But the side effects of high dose immunosuppression and hormone can not be ignored. Many clinical studies showed that more than20%of the patients with high dose CTX, methylprednisolone treatment can occur the symptoms of infection, such as herpes zoster, pneumonia, urinary system infection and meningitis. Especially, the probability of complications in the immunocompromised patients after treating with pulse therapy increased greatly.The infection has become one of the main causes of death in patients with SLE.
In recent years, the role of Chinese medicine in the treatment of SLE has caused some medical attention, In the ancient literature of traditional Chinese medicine, although there is not the same discussion named systemic lupus erythematosus disease, the similar or related is discussed extensively. After thousands of years of accumulation, the paper discusses involved the different aspects about SLE. According to its clinical symptoms, many Chinese scholars will it belongs to "HuDieBan","Yin and Yang poison","Sun boils" category. In the current domestic physician of TCM have knowledge about SLE, most believe that the foundation of this disease is inadequate natural endowment. So filling its deficiency account for important position in the study of SLE. Representative drugs such as Liuwei dihuangwan, Bailing capsule and so on.
Liuwei dihuangwan is Yin and Yang on behalf of the party with Ziyin kidney function. The prescription Composed of Radix rehmanniae, Cortex Moutan, Oriental waterplantain rhizome, dogwood, yam, Poria six taste medicine.In the prescription Radix rehmanniae is on nourishing kidney essence role mainly, with dogwood nourishing liver and kidney and astringing essence, with Yam tonifying spleen and kidney and solid essence. Poria cocos light infiltration spleen wet to help Yam tonifying spleen. Poria cocos ooze water wet, making water the downward and out of body. Alisma discharge kidney fire and prevent the Rehmannia greasy. Cortex Moutan cleare liver fire, cool blood stasis, in addition to the bone steaming hot and wet of dogwo. The curative Effect of this prescription is exact after hundreds of years for medical use. This prescription is aigorous and become the representative prescription of nourishing kidney yin. Modern pharmacological studies confirmed: Rehmannia glutinosa have excited or adjusted adrenocortical axis function.lt can antagonize the inhibition of exogenous hormone on pituitary adrenal, delay liver decomposition of cortical hormone, and prompte the cortical hormone of the blood elevated. It can keep the physiological effects of glucocorticoid and reduce the side effects of glucocorticoid induced also.
Bailing capsule consists of Artificial Cordyceps mycelium.It is consistent with natural Cordyceps sinensis, and has nourishing the lung and kidney, Yijing gas effect. Recent studies suggest that caterpillar fungus has antioxidant effect, improve organism cellular immunity, and reduce the side effects caused by glucocorticoid in protein decomposition and infections. It has the function of bidirectional regulation of human immune cells, can reduce the immunosuppressive drug side effects,but also have synergistic effect with immunosuppressive drugs. Cordyceps has good anti-inflammatory and immunomodulating effects, no hormone kind of side effects. The research reports about the Bailing Capsule Combined with Liuwei dihuangwan reducing the side effects caused by glucocorticoid and immune agents in SLE patients are few, especially on the intervention study of SLE complicated with infection. In the clinical practice of the past few years, we have been trying to give Liuwei dihuangwan combined with Bailing Capsule in treating SLE patients. Results showed that, increasing the above treatment can effectively reduce the risk of infection and can reduce the degree of infection in SLE patients; but also improve the clinical efficacy, reduce the mortality rate. Therefore, we did this research.
Objective
1. to learn about the risk factors of systemic lupus erythematosus (SLE) patients complicated with infection and the infections in two groups after the treatment, observating the intervention effect about regulation of immune medicine (bailing capsule and Liuwei Dihuangwan) on the SLE patients with immunosuppression and hormone therapy. So as to explore the therapeutic regimen of reducing SLE infection, looking for the effective and relatively safe ways for the treatment of SLE.
2. to observate the expression levels of IL-2in two groups before and after treatment, concluding the possible mechanism of immune medicine reducing SLE infection in cellular immune.
Methods
1. Analysis of SLE patients with risk factors for infection
Retrospective study of82cases of patients with SLE on our hospital from January1,2010to December31,2012. The variables include gender, age, body mass, disease course, white blood cell, HGB, plasma albumin level, value IL2, C3, CRP, immune inhibitors and hormone application. To observe the incidence of infection and the correlation between the incidence of infection with these variables. In this study, the infection include bacterial infection, viral infections, fungal infection, involving the respiratory system, urinary system, skin and soft tissue, the central nervous system and blood system,etc.
2. To observe the clinical curative effect and infection of two groups.
2.1Retrospective study from the January1,2010to December31st,2012was associated with61cases of SLE patients with renal involvement and or interstitial lung disease (from the standard hospital treatment and regular follow-up of patients, selected cases that do not merge infection at first diagnosed). According to the severity of the disease were randomly divided into two groups. There were31cases in the Chinese and Western medicine treatment group, including4males,27females, age13to65years old, and average duration is36.2months. The western medicine control group contain30patients, including2males,28females, age14to63year old, and average duration is35.8months.
2.2Method of administration
The western medicine control group:The western medicine control group are given with glucocorticoid and cyclophosphamide therapy. A、glucocorticoid: prednisone(lmg/kg/d) is usually one-time taking in the morning, after two weeks in stable disease or eight weeks, then began to slow reduction at the rate of10%every two weeks until the prednisone0.5mg/kg/d, and treatment of hormone doses as far as possible little to10mg/d. In the reduction of drug in the process, if the condition is not stable, can temporarily maintain the original dose. B、 cyclophosphamide:once a month in the first half of the year after stability to every march(the dosage of16-20mg/kg added into250ml physiological saline for intravenous drip, generalty erery day0.4-0.6g, stay for two days). To the serious cases,we can use large dose (prednisone≥2mg/kg/d) and methylprednisolone pulse therapy. MP available to500-1000mg, one times a day, adding5%glucose slow intravenous drip for one to two hours, for three consecutive days to one course of treatment, treatment interval between five to thirty days. Oral prednisone (lmg/kg/d-2mg/kg/d) are used during interval or after pulse therapy. The course of treatment and interval length depend on the specific disease.
The Chinese and Western medicine treatment group:on the basis of the western medicine plus Liuwei Dihuagnwan(8pills, three times a day) and Bailing Capsule(1.0g, three times a day).
2.3Observation index:Through the observation of ESR, CRP, C3, C4, IG, ANA, ds-DNA, SLEDAI score, blood routine test, liver and kidney function, to compare curative effect of two kinds of therapy and the infection (pulmonary infection, urinary tract infection, infection of the central nervous system,etc.). Two groups both were treated for18months, and assessed at6,12,18months after the treatment.
3. Effect of Bailing Capsule Combined with Liuwei Dihuagnwan on serum IL-2level in patients with SLE.
Respectively in the two groups of patients at the first diagnosis and treatment of6,12,18months later, the conventional separation of peripheral serum3ml, then save it in the spare-80°C. According to the test operation provided by IL-2kit instructions, testing the patients' serum level of IL-2.
Results
1. The study found that the risk factors of SLE patients with infections include defect of complement (Complement C3), immune abnormalities (Blood leukocyte count、Plasma albumin levels),disease activity, hormone impact, long-term immunosuppressive therapy, number of the affected organs, duration of hospitalization. They have significant difference by statistics analysis(P<0.05). Infection had no correlation with sex, age, body mass, and disease duration (P>0.05). The active parts of SLE with infection mainly concentrated in the respiratory tract and urinary tract. The pathogenic bacteria were mainly gram-negative bacteria. Conditional pathogenic bacteria is relatively more.
2. The total effective rate of treatment group (83.8%) was higher than that of the control group (73.3%), the difference was statistically significant. After6treatment months in treatment group the infection rate was9.67%, control group16.67%.After12treatment months, the infection rate was12.9%, control group20.8%;18months later, the infection rate was16.67%in treatment group, control group25.00%. The infection rate of treatment group was significantly lower than the control group(P<0.05).
3. The level of IL-2of the treatment group was significantly higher than the control group.6months,12months,18months later, interleukin2levels of treatment group respectively were6.97±1.32pg/ml,7.26±1.25pg/ml,7.54±1.24pg/ml. Interleukin2levels of control group respectively was5.29±1.26, pg/ml,5.42±0.99pg/ml,5.63±1.15pg/ml. There was statistical significance between the two groups (P<0.05). The levels of IL-2before treatment was5.39±1.06pg/ml in the control group, the treatment group5.41±1.03pg/ml.
Conclusion
1.The immunosuppressive therapy in patients with systemic lupus erythematosus is easy to cause infection, it is also an important cause of patients with multiple organ failure and even death. Long term high dose immunosuppression, corticosteroid therapy, low immunity(low blood leukocyte count,Plasma albumin levels drop), low levels of C3、number of the affected organs, duration of hospitalization, the activity of disease were independent risk factors of infection.
2. Bailing Capsule combined with Liuwei Dihuangwan can effectively alleviate the complication that caused by immune inhibitor and hormone in the treatment of systemic lupus erythematosus, and increase clinical therapeutic effect. Besides, it can reduce the risk and the symptoms of infection. Therefore, they aer an effective therapeutic regimen for clinicians in the treatment of systemic lupus erythematosus.
3. Bailing Capsule combined with Liuwei Dihuagnwancan increased the secretion of IL-2in patients with systemic lupus erythematosus. This treatment can reduce the infection rate in the systemic lupus erythematosus, it may be associated with increased IL-2that can promote the patients in stable disease. This means they can adjust immune function to improve the lungs, kidneys and other organs function from the side, and can improve the immunity function.
Significance
1.Technique route of this research is practical and clear. This research mainly observed the effect about the regulation of immune medicine on immunosuppressive therapy in patients with systemic lupus erythematosus complicated with infection. At present the same study rarely seen at home and abroad. The research content is novel and clinical practicability is very strong. This study broaden the research perspective and lay a certain foundation for further research.
2.This study examined the level of IL-2in the patients with systemic lupus erythematosus, and found that the increased IL-2of the treatment group is contacted with the reduce of infection in this group. The report provides the basis to investigate the mechanism of regulation of immune medicine through cytokine network. In addition, it also provides a valuable paradigm for evaluation about this kind of drug on the therapeutic effects.
系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种自身免疫性疾病。该病是以产生多种自身抗体,并由免疫反应介导炎症为特征的累及多器官、多系统的弥漫性结缔组织病,病情轻重不一。近20年来,环磷酰胺(CTX)、糖皮质激素冲击疗法作为重型SLE诱导缓解的常用疗法。狼疮危象常常需要CTX、大剂量甲基泼尼松龙或加用大剂量免疫球蛋白冲击治疗。虽然近年来SLE的治疗方面有许多新进展,但国内外仍以糖皮质激素加免疫抑制剂为主。它们常能有效控制疾病活动、改善病情,有效提高了SLE患者的存活率。但是大剂量免疫抑制剂和糖皮质激素的副作用及并发症也不容忽视。许多临床研究表明,大剂量CTX、甲基泼尼松龙冲击治疗后出现诸如带状疱疹、肺炎、泌尿系感染及脑炎等感染,可见于20%以上的患者。特别是经CTX或甲基泼尼松龙冲击治疗后的患者免疫力低下,并发感染的几率大大增加,已成为SLE患者死亡的主要原因之一。
近年来,中医中药在SLE治疗中的作用逐渐引起人们的重视。中医古代文献中虽没有以系统性红斑狼疮为病名的论述,但对其相似或相关论述甚广,历经数千年之积淀,对其论述涉及本病诸多方面。根据其临床症状表现,不少中医学者将它归属于“蝴蝶斑”、“阴阳毒”、“日晒疮”等范畴。目前国内中医学家对此病证认识颇多,大都认为该病的基础是先天禀赋不足。所以补其不足在系统性红斑狼疮中的研究中占重要地位。代表药物如六味地黄丸,此外百令胶囊、白芍总苷等也被常用于SLE的辅助治疗。
六味地黄丸是阴中求阳的代表方,具有滋阴补肾的作用。方中由熟地、丹皮、泽泻、山茱萸、山药、茯苓六味药组成。方中用熟地滋肾填精为主,辅以山茱萸养肝肾而涩精,山药补脾肾而固精又配茯苓淡渗脾湿以助山药益脾,茯苓渗水利湿,使浊水下泻,排出外体,泽泻清泄肾火,并防熟地之滋腻,丹皮清泄肝火,凉血散瘀,除骨蒸之热,并制山茱萸之湿。此方历经数百年医家运用其疗效确切,组方严谨合理,成为滋补肾阴的代表方。现代药理研究证实：六味地黄汤能提高模型动物的白细胞介素(IL)-2活性,IL-2具有促进并维持T淋巴细胞在体内外的生长,参与B淋巴细胞抗体产生,本方还能增强红细胞的免疫功能,方中熟地黄有兴奋或调节肾上腺皮质轴功能,拮抗外源性激素对垂体-肾上腺皮质的抑制作用,延缓肝脏对皮质激素的分解,使血中皮质激素升高。六味地黄方不是单纯的免疫促进剂或免疫抑制剂,而是通过调节机体免疫平衡而发挥作用。
百令胶囊主要成分为人工虫草菌丝体干粉,与天然虫草效果基本一致,具有补肺肾,益精气的功效。现代药理研究显示百令胶囊具有有抗氧化,提高机体细胞免疫力,升高机体白细胞,调节血脂,抗炎等作用,能减轻长期应用糖皮质激素引起的蛋白质分解增加、提高抗感染能力；且对机体免疫系统具有双向调节的功能,既可减轻免疫抑制药的毒副作用,又协同其他免疫抑制药发挥作用。综上百令胶囊具有一定的抗炎及调节免疫作用而不会引起激素样副作用。
百令胶囊和六味地黄丸联合应用对于减少因免疫制剂和激素治疗SLE所致的副作用的研究报道较少,尤其是对SLE并发感染的干预作用研究更少。在过去几年的临床实践中,我们尝试用六味地黄丸联合百令胶囊辅助治疗SLE患者,结果显示,可以有效减低SLE患者感染的几率并能降低感染程度；从而提高临床疗效,降低病死率。为此,特做此相关研究。
目的
1.观察系统性红斑狼疮(SLE)患者并发感染的危险因素,并通过两组治疗后伴发的感染情况,观察中成药(百令胶囊及六味地黄丸)对应用免疫抑制和糖皮质激素治疗的SLE患者的干预作用,从而探寻减少SLE伴发感染的治疗方案,寻找有效且相对安全的治疗方法。
2.观察两组治疗前后的IL-2表达水平,推断调节免疫中成药减少SLE感染在细胞免疫方面的可能机制。
方法
1.分析SLE患者出现感染的危险因素：回顾研究我院和九江学院附属医院风湿科2009年1月1日-2012年1月1日收治的SLE患者82例,以性别、年龄、体质量、病程,血白细胞、血浆白蛋白水平,IL-2、C3、CRP数值,免疫抑制剂及激素应用情况为自变量,观察患者的感染发生率,以及感染发生率与这些指标之间的相关性。本研究中感染包括细菌感染、病毒感染、真菌感染；感染涉及呼吸系统、泌尿系统、皮肤和软组织、中枢神经系统及血液系统等。
2.观察两组的临床疗效及两组感染情况：
2.1研究对象：
回顾性研究2009年1月1日～2012年1月1日伴有肾脏受累和或肺间质性病变的SLE患者61例(均来自规范治疗并定期复诊的患者,入选病例首诊时经常规检测并未合并感染)随机分成两组。中西医结合治疗组31例,男性4例,女性27例；年龄13-65岁,病程平均36.2月。西药对照组30例,其中男性2例,女性28例；年龄14-63岁,病程平均35.8月。两组患者在性别、年龄、病程、病情等方面经检验差异无统计学意义。
2.2给药方法：
对照组：对照组采用糖皮质激素加环磷酰胺进行治疗。A、糖皮质激素：泼尼松lmg/kg/d通常晨起1次服用,待患者病情稳定后2周或疗程8周内,以每2周减10%的速度缓慢减量,减至泼尼松0.5mg/kg/d,治疗的激素剂量尽量小至泼尼松10mg/d。在减药过程中,如果病情不稳定,可暂时维持原剂量不变。B、环磷酰胺：前半年每月一次,稳定后改为每三月一次(用量16-20mg/kg加入生理盐水250m1中静脉滴注,一般每天0.4-0.6g,连用两天)。对有病情严重者,可以使用较大剂量(泼尼松≥2mg/kg/d)甚至甲基泼尼松龙冲击治疗,甲基泼尼松龙可用至500～1000mg,每天1次,加入5%葡萄糖慢静脉滴注1～2小时,连续3天为1疗程,疗程间隔期5-30天,间隔期和冲击后需口服泼尼松1mg/kg/d-2mg/kg/d,疗程和间隔期长短视具体病情而定。治疗组：在对照组基础上加用六味地黄丸(8丸,每日三次)及百令胶囊(1.0g,每日三次)。
2.3观察指标：通过SLEDAI评分观察病情；测定血常规、尿常规,ESR, CRP, C3、C4,IG,免疫荧光抗核抗体(ANA),抗ds-DNA抗体,肝肾功能等变化,比较两种疗法的治疗效果和伴发感染情况(肺部感染、泌尿系感染、中枢神经系统感染等)。两组疗程均为18个月,分别在治疗6、12、18个月后评估患者病情。
3.百令胶囊联合六味地黄丸对SLE患者血清IL-2水平的影响
分别在两组患者初诊及治疗后6、12、18个月后,常规分离患者外周血清3m1,并将其置于-80。C下保存备用。按照人IL-2ELISA检测试剂盒中所提供的检测操作说明,检测相应患者血清中IL-2水平。
结果
1.结果显示SLE患者伴发感染的易感因素主要有补体缺陷(补体C3),糖皮质激素冲击、长期免疫抑制剂使用,病情活动性,累及系统和脏器的数量,住院时间相关(P<0.05)；与性别、年龄、体质量、病程无明显相关(P>0.05)；SLE合并感染以呼吸道部感染和泌尿系感染为主；病原菌以革兰阴性菌为主,条件致病菌相对较多。
2.临床研究得出：治疗组总有效率(83.8%)高于对照组(73.3%),其差异有统计学意义。治疗6个月后治疗组感染率9.67%,对照组16.67%；治疗12个月后治疗组感染率12.90%；对照组20.68%；18个月后感染率,治疗组16.67%,对照组为25%,治疗组感染率明显低于对照组,经统计学分析有显著差异(P<0.05)。
3.治疗组患者IL-2水平显著高于对照组,治疗6个月、12个月、18个月后,治疗组白介素2水平分别为6.97±1.32pg/ml,7.26±1.25pg/ml；7.54±1.24pg/ml;对照组为5.29±1.26pg/ml；5.42±0.99pg/ml；5.63±1.15pg/ml.经统计学分析两组数据有差异(P<0.05)。
结论
1.对照组(单纯免疫抑制治疗系统性红斑狼疮组),患者易伴发感染,这也是导致患者多脏器功能衰竭甚至死亡的重要原因。长期大剂量免疫抑制剂、激素冲击治疗,免疫力低下(血白细胞计数降低、血浆白蛋白水平下降等),C3水平低下、累及的脏器个数,住院时间延长、病情活动性是伴发感染的独立危险因素。
2.百令胶囊联合六味地黄丸可以有效缓解免疫抑制剂和激素治疗系统性红斑狼疮导致的并发症,增加临床疗效,可以减少SLE患者出现感染的几率,减轻感染症状。故可以作为临床医师治疗系统性红斑狼疮的一种有效治疗方案。
3.百令胶囊联合六味地黄丸增加了系统性红斑狼疮患者IL-2的分泌；能减少系统性红斑狼疮并发感染率,可能与增高的IL-2可促进患者本病的病情稳定有关。从侧面说明二者有通过调节免疫作用达到改善肺部、肾脏等脏器的功能状态,提高患者免疫力的作用。
意义
1.本研究主要观察了调节免疫中成药对系统性红斑狼疮患者免疫抑制治疗后并发感染率的影响。目前国内外很少见到相同的研究报告,研究内容新颖,临床实用性强；拓宽了研究视野,为以后深入研究打下了一定基础。
2.本研究检测了系统性红斑狼疮患者的IL-2水平,发现实验组的IL-2水平的增高与该组的感染率下降相平行,从而为通过细胞因子网络调控领域探讨调节免疫中成药作用机理提供了基础；为该类药治疗效果的评判提供了一个有参考价值的范例。
Background
Systemic lupus erythematosus(SLE) is an autoimmune disease. It is a kind of diffuse connective tissue disease characterized by producing a variety of antibodies and immune response mediated inflammation. It related to involvement of several visceral organs. The condition ranges from mild to severe. In recent20years, the cyclophosphamide (CTX) and corticosteroid therapy were used as a classic method for the induction therapy of heavy SLE internationally. Lupus crisis often need combined with CTX, the impact of large dose methylprednisolone and immune globulin or three treatment. At present, there are many new advances in the treatment of SLE. However, the treatment is still dominated by hormone and immunosuppressant at home and abroad. They can effectively control the disease activity, improve the condition and the survival rate of patients with SLE. But the side effects of high dose immunosuppression and hormone can not be ignored. Many clinical studies showed that more than20%of the patients with high dose CTX, methylprednisolone treatment can occur the symptoms of infection, such as herpes zoster, pneumonia, urinary system infection and meningitis. Especially, the probability of complications in the immunocompromised patients after treating with pulse therapy increased greatly.The infection has become one of the main causes of death in patients with SLE.
In recent years, the role of Chinese medicine in the treatment of SLE has caused some medical attention, In the ancient literature of traditional Chinese medicine, although there is not the same discussion named systemic lupus erythematosus disease, the similar or related is discussed extensively. After thousands of years of accumulation, the paper discusses involved the different aspects about SLE. According to its clinical symptoms, many Chinese scholars will it belongs to "HuDieBan","Yin and Yang poison","Sun boils" category. In the current domestic physician of TCM have knowledge about SLE, most believe that the foundation of this disease is inadequate natural endowment. So filling its deficiency account for important position in the study of SLE. Representative drugs such as Liuwei dihuangwan, Bailing capsule and so on.
Liuwei dihuangwan is Yin and Yang on behalf of the party with Ziyin kidney function. The prescription Composed of Radix rehmanniae, Cortex Moutan, Oriental waterplantain rhizome, dogwood, yam, Poria six taste medicine.In the prescription Radix rehmanniae is on nourishing kidney essence role mainly, with dogwood nourishing liver and kidney and astringing essence, with Yam tonifying spleen and kidney and solid essence. Poria cocos light infiltration spleen wet to help Yam tonifying spleen. Poria cocos ooze water wet, making water the downward and out of body. Alisma discharge kidney fire and prevent the Rehmannia greasy. Cortex Moutan cleare liver fire, cool blood stasis, in addition to the bone steaming hot and wet of dogwo. The curative Effect of this prescription is exact after hundreds of years for medical use. This prescription is aigorous and become the representative prescription of nourishing kidney yin. Modern pharmacological studies confirmed: Rehmannia glutinosa have excited or adjusted adrenocortical axis function.lt can antagonize the inhibition of exogenous hormone on pituitary adrenal, delay liver decomposition of cortical hormone, and prompte the cortical hormone of the blood elevated. It can keep the physiological effects of glucocorticoid and reduce the side effects of glucocorticoid induced also.
Bailing capsule consists of Artificial Cordyceps mycelium.It is consistent with natural Cordyceps sinensis, and has nourishing the lung and kidney, Yijing gas effect. Recent studies suggest that caterpillar fungus has antioxidant effect, improve organism cellular immunity, and reduce the side effects caused by glucocorticoid in protein decomposition and infections. It has the function of bidirectional regulation of human immune cells, can reduce the immunosuppressive drug side effects,but also have synergistic effect with immunosuppressive drugs. Cordyceps has good anti-inflammatory and immunomodulating effects, no hormone kind of side effects. The research reports about the Bailing Capsule Combined with Liuwei dihuangwan reducing the side effects caused by glucocorticoid and immune agents in SLE patients are few, especially on the intervention study of SLE complicated with infection. In the clinical practice of the past few years, we have been trying to give Liuwei dihuangwan combined with Bailing Capsule in treating SLE patients. Results showed that, increasing the above treatment can effectively reduce the risk of infection and can reduce the degree of infection in SLE patients; but also improve the clinical efficacy, reduce the mortality rate. Therefore, we did this research.
Objective
1. to learn about the risk factors of systemic lupus erythematosus (SLE) patients complicated with infection and the infections in two groups after the treatment, observating the intervention effect about regulation of immune medicine (bailing capsule and Liuwei Dihuangwan) on the SLE patients with immunosuppression and hormone therapy. So as to explore the therapeutic regimen of reducing SLE infection, looking for the effective and relatively safe ways for the treatment of SLE.
2. to observate the expression levels of IL-2in two groups before and after treatment, concluding the possible mechanism of immune medicine reducing SLE infection in cellular immune.
Methods
1. Analysis of SLE patients with risk factors for infection
Retrospective study of82cases of patients with SLE on our hospital from January1,2010to December31,2012. The variables include gender, age, body mass, disease course, white blood cell, HGB, plasma albumin level, value IL2, C3, CRP, immune inhibitors and hormone application. To observe the incidence of infection and the correlation between the incidence of infection with these variables. In this study, the infection include bacterial infection, viral infections, fungal infection, involving the respiratory system, urinary system, skin and soft tissue, the central nervous system and blood system,etc.
2. To observe the clinical curative effect and infection of two groups.
2.1Retrospective study from the January1,2010to December31st,2012was associated with61cases of SLE patients with renal involvement and or interstitial lung disease (from the standard hospital treatment and regular follow-up of patients, selected cases that do not merge infection at first diagnosed). According to the severity of the disease were randomly divided into two groups. There were31cases in the Chinese and Western medicine treatment group, including4males,27females, age13to65years old, and average duration is36.2months. The western medicine control group contain30patients, including2males,28females, age14to63year old, and average duration is35.8months.
2.2Method of administration
The western medicine control group:The western medicine control group are given with glucocorticoid and cyclophosphamide therapy. A、glucocorticoid: prednisone(lmg/kg/d) is usually one-time taking in the morning, after two weeks in stable disease or eight weeks, then began to slow reduction at the rate of10%every two weeks until the prednisone0.5mg/kg/d, and treatment of hormone doses as far as possible little to10mg/d. In the reduction of drug in the process, if the condition is not stable, can temporarily maintain the original dose. B、 cyclophosphamide:once a month in the first half of the year after stability to every march(the dosage of16-20mg/kg added into250ml physiological saline for intravenous drip, generalty erery day0.4-0.6g, stay for two days). To the serious cases,we can use large dose (prednisone≥2mg/kg/d) and methylprednisolone pulse therapy. MP available to500-1000mg, one times a day, adding5%glucose slow intravenous drip for one to two hours, for three consecutive days to one course of treatment, treatment interval between five to thirty days. Oral prednisone (lmg/kg/d-2mg/kg/d) are used during interval or after pulse therapy. The course of treatment and interval length depend on the specific disease.
The Chinese and Western medicine treatment group:on the basis of the western medicine plus Liuwei Dihuagnwan(8pills, three times a day) and Bailing Capsule(1.0g, three times a day).
2.3Observation index:Through the observation of ESR, CRP, C3, C4, IG, ANA, ds-DNA, SLEDAI score, blood routine test, liver and kidney function, to compare curative effect of two kinds of therapy and the infection (pulmonary infection, urinary tract infection, infection of the central nervous system,etc.). Two groups both were treated for18months, and assessed at6,12,18months after the treatment.
3. Effect of Bailing Capsule Combined with Liuwei Dihuagnwan on serum IL-2level in patients with SLE.
Respectively in the two groups of patients at the first diagnosis and treatment of6,12,18months later, the conventional separation of peripheral serum3ml, then save it in the spare-80°C. According to the test operation provided by IL-2kit instructions, testing the patients' serum level of IL-2.
Results
1. The study found that the risk factors of SLE patients with infections include defect of complement (Complement C3), immune abnormalities (Blood leukocyte count、Plasma albumin levels),disease activity, hormone impact, long-term immunosuppressive therapy, number of the affected organs, duration of hospitalization. They have significant difference by statistics analysis(P<0.05). Infection had no correlation with sex, age, body mass, and disease duration (P>0.05). The active parts of SLE with infection mainly concentrated in the respiratory tract and urinary tract. The pathogenic bacteria were mainly gram-negative bacteria. Conditional pathogenic bacteria is relatively more.
2. The total effective rate of treatment group (83.8%) was higher than that of the control group (73.3%), the difference was statistically significant. After6treatment months in treatment group the infection rate was9.67%, control group16.67%.After12treatment months, the infection rate was12.9%, control group20.8%;18months later, the infection rate was16.67%in treatment group, control group25.00%. The infection rate of treatment group was significantly lower than the control group(P<0.05).
3. The level of IL-2of the treatment group was significantly higher than the control group.6months,12months,18months later, interleukin2levels of treatment group respectively were6.97±1.32pg/ml,7.26±1.25pg/ml,7.54±1.24pg/ml. Interleukin2levels of control group respectively was5.29±1.26, pg/ml,5.42±0.99pg/ml,5.63±1.15pg/ml. There was statistical significance between the two groups (P<0.05). The levels of IL-2before treatment was5.39±1.06pg/ml in the control group, the treatment group5.41±1.03pg/ml.
Conclusion
1.The immunosuppressive therapy in patients with systemic lupus erythematosus is easy to cause infection, it is also an important cause of patients with multiple organ failure and even death. Long term high dose immunosuppression, corticosteroid therapy, low immunity(low blood leukocyte count,Plasma albumin levels drop), low levels of C3、number of the affected organs, duration of hospitalization, the activity of disease were independent risk factors of infection.
2. Bailing Capsule combined with Liuwei Dihuangwan can effectively alleviate the complication that caused by immune inhibitor and hormone in the treatment of systemic lupus erythematosus, and increase clinical therapeutic effect. Besides, it can reduce the risk and the symptoms of infection. Therefore, they aer an effective therapeutic regimen for clinicians in the treatment of systemic lupus erythematosus.
3. Bailing Capsule combined with Liuwei Dihuagnwancan increased the secretion of IL-2in patients with systemic lupus erythematosus. This treatment can reduce the infection rate in the systemic lupus erythematosus, it may be associated with increased IL-2that can promote the patients in stable disease. This means they can adjust immune function to improve the lungs, kidneys and other organs function from the side, and can improve the immunity function.
Significance
1.Technique route of this research is practical and clear. This research mainly observed the effect about the regulation of immune medicine on immunosuppressive therapy in patients with systemic lupus erythematosus complicated with infection. At present the same study rarely seen at home and abroad. The research content is novel and clinical practicability is very strong. This study broaden the research perspective and lay a certain foundation for further research.
2.This study examined the level of IL-2in the patients with systemic lupus erythematosus, and found that the increased IL-2of the treatment group is contacted with the reduce of infection in this group. The report provides the basis to investigate the mechanism of regulation of immune medicine through cytokine network. In addition, it also provides a valuable paradigm for evaluation about this kind of drug on the therapeutic effects.
引文
[1]汤建芳,茹祥斌,顾国明,等.地黄低聚糖对小鼠免疫和造血功能的作用[J].中药药理与临床,1997,13(5)：19-21.
[2]杜伟锋,王明艳,蔡宝昌.山茱萸炮制前后多糖对小鼠免疫功能的影响[J]·中药材,2008,31(5)：715-717.
[3]苗明三,方晓燕,杨云,等.山茱萸多糖免疫兴奋作用的研究[J].河南中医,2002,(05)：24-25.
[4]赵世萍,陈玉武,郭景珍,等.山茱萸总甙的抗炎免疫抑制作用[J].中日友好医院学报,1996,10(4)：295-298.
[5]陈涛·山茱萸水提液对骨质疏松模型小鼠骨形态学影响[J]·天津药学,2003,15(4)：5.
[6]郑素玲.山药对免疫机能低下小鼠耐缺氧能力的影响[J].动物医学进展,2010,31(2)：70-73
[7]程林,陈斌,蔡宝昌.山药多糖对2型糖尿病大鼠降糖机理的研究〔J〕.中药新药与临床药理,2006：17(2)：86-9.
[8]尹春萍,吴继洲·滓泻及其活性成分免疫调节作用研究进展(J〕·中草药,2001,32(12)：1132·
[9]刘春生,王海.药用动植物种养加工技术·牡丹皮[M].北京：中国中医药出版社,2001：77-85.
[10]王静,胡明华,董燕,等. 茯苓多糖对免疫抑制小鼠黏膜淋巴组织及脾脏中CD3+和CD19+细胞变化的影响[J]. 中国免疫学杂志,2011,27：228-231.
[11]杜标炎,李道中,王培圳.肾阳虚造型及补肾中药对大鼠免疫功能的影响[J].广州中医药大学学报,1996,13(1)：37-38.
[12]杨胜,张永祥,吕晓东,等.六味地黄汤活性部位3A的免疫调节作用机制研究[J].中国中西医结合杂志,2001,21(2)：119-120.
[13]吴军,赵凤鸣,王明艳,等. 四君子汤、六味地黄汤对环磷酰胺致小鼠免疫抑制的拮抗作用实验研究[J]. 四川中医,2007,25(10)：12-14.
[14]练颖 郑萍 官晓红 胡谦 雷丽华 陶黎 六味地黄丸对激素和免疫抑制剂治疗系统性红斑狼疮干预作用的研究[J]四川中医2006年第24卷第2期：20-21
[15]李萍,石晓宏,王风连. 六味地黄丸和地黄的免疫药理研究[J]. 中国免疫学杂志,1987,3(5)：296
[16]聂伟,张永祥,茹祥斌. 六味地黄汤免疫调节活性成分化学分离的药理学导向评价[J]. 中国中西医结合杂志,1998,18(5)：287
[17]聂伟,张永祥,茹祥斌. 六味地黄汤活性部分CA4的免疫调节作用研究[J]. 中药药理与临床,1998,14(2)：1
[18]宋艳丽,郭俐宏,朱克刚 百令胶囊对大鼠急性肾缺血再灌注损伤的保护作用[J]陕西医学杂志2014年1月第43卷第1期：25-26,37
[19]田晓,冯晓明,孟晓华,百令胶囊对环孢素A肾病大鼠免疫功能影响[J] Chinese Journal of Coal Industry Medicine sep.2013,VOL.16, NO.9:1516-1518
[20]宋艳丽,刘兴林,陈德森 百令胶囊对实验性糖尿病大鼠肾脏的保护作用[J]齐鲁医学杂志2014年2月第29卷第1期Med J Qilu, February 2014, Vol 2.9, No.1:35-37
[21]黄虹,杨丕坚,李舒敏,吕以培,黄中莹百令胶囊对Graves病患者T淋巴细胞亚群的影响[J]中国实验方剂学杂志2013年10月第19卷第20期：296-299
[22]陈丽,贾晓民,邵青 百令胶囊对尘肺患者外周血 T细胞亚群的影响及其临床意义[J]中国临床研究 2013年11月第26卷第11期：1172-1173
[23]李暖,陈新德,杨达胜,赵德安,毕凌云 百令胶囊对大鼠肾小管间质纤维化的防治作用[J]中国中西医结合肾病杂志2007年4月第8卷第4期：227-228
[24]吴艺红,王实,百令胶囊对肺心病病人免疫功能作用的研究[J]中国实验方剂学杂志1995年第1卷第1期：45-46
[25]刘宝忠,张花,杨坤,吴海燕,廖有乔 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响[J]医药导报2009年6月第28卷第6期：727-728
[26]王晓乐,邱潮林,吴秀梅等.SLE患者外周血T细胞亚群凋亡特点及其相关机制的研究[J].中国免疫学杂志,2010,26(04)：348-353.
[27]Aleocer VJ, Alarcon SD. Deereased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus[J]. J Clin Inves.1982,69:1388.
[28]Skanae T, Murkawaa Y, Suzuki N,et al. Familial occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosus[J]. Am J Med.1989,385:390.
[29]Warrington RJ, Sauder PJ, Homik J, et al. Reversible interleukin-2 response defects in system lupus erythematosus[J]. Clin ExP Immunol.1989,163:167.
[30]BounpasDT,AustinHA,VaughnEM,etal.Contolled trail of pulse methylpredisolong verse two regiments of pulse cyclophosphamide in sever lupus nephritis[J]Lancet,1992,340:741-745
[31],储萍,赵亚军,李卫党等.系统性红斑狼疮患者外周血T辅助细胞因子的表达, 江苏大学学报(医学版)杂志.2002,：12)4：335-336
[32]Aleoeer VJ,etal. Defeetive monoeyte Produetion of and T lymphocyte response to interleukin-1 in the peripheral blood of patients with SLE.Clinexp Immunol 1984;54:125.
[33]AleoeerVJ,etal.Defeetive monoeyte Produetion of and T LymPhocyte response to interleuk in the PeriPheral blood of Patients withSLE.ClinExP Immunol 1984, (5) 4:125.
[34]Frazer TH,etal.T IymPhoeyte subpopulations Defined by two sets of monoclonal antibodies in chronie active hepatitis and systemie lupus ery-thematosus. Clin Exp Immunol.1982;50:107.
[35]RapPaPortRS,Dodge GR.Prostaglandin E inhibits the produetion of human interleukin—2.J Exp Med 1982,155:943.
[36]刘亚光,尹培达IsL—R与SLE的临床表现和自身抗体的相关性,中国免疫学杂志.1994,3(10)：177
[37]杨剑辉,梁俊林,汤俊达等.环磷酞胺冲击疗法对狼疮病人白介素2受体表达的影响.前卫医药杂志.1994,(11)3：139-140
[38]彭永麟,胡建达,吕联煌.免疫性疾病患者血清可溶性白细胞介素一2受体水平.福建医学院学报,1995(24)4：321-322
[39]Wongchinsri J, Tantawichien T, OsirMi, et al Infection in Thaipatients with systemic lupus erythematosus a review of hospitalized patients.Med Assoc Tha,i 2002,85(Suppll):S34-39.
[40]RosnerS,GinzlerEM,Diamond HS,Weiner M,Schlesinger M,Fries JF,wasner C,Medsger TA Jr,Ziegler G,Klippel JH,Hadler NM,Albert DA,Hess EV,Spencer-Green G,Grayzel A,Worth D,Hahn Bh,Bernett EV.A multicenter study of outcome in systemic lupus erythematosus.2.Causes of death. Arthritis Rheum,1982,25:612-617
[41]邹晋梅,杨静,刘毅 系统性红斑狼疮感染状况及死亡原因分析[J]西部医学2011年2月第23卷第2期：356-358
[42]三森明夫 风湿病诊疗笔记[M] 北京；人民军医出版社,2013：44
[43]李海瑞 益气补肾汤治疗狼疮性肾炎气阴两虚型的临床研究[D]福建福建 中医药大学2012：1
[44]蔡小燕,许艳丽,林小军,傅君舟等 黄芪注射液对系统性红斑狼疮患者细胞凋亡和免疫功能的影响[J]中国中西医结合杂志2006年5月第26卷第5期：443-445
[45]杜彭露糖结合凝集素(MBL)在系统性红斑狼疮(SLE)及其合并感染患者血清含量的检测及意义[d]天津：天津中医科大学2010年：Ⅰ-Ⅱ
[46]Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies[J]. Curr Opin Rheumatol,2003,15(5):528-534.
[47]Ginzle E, et al.Computer analysis If factors influening frequency of infection in systemic lupus erythematosus. Arthritis Rheum,1978,21:37-44
[48]Bosch X, Guilabert A, Pallares L, et al. Infections in systemic lupus erythematosus:a prospective and controlled study of 110 patients[J]. Lupus,2006,15(9):584-589.
[49]Paton NI, Cheong IK, Kong NC, et al. Risk factor for infection in Malaysian patient with systimic Lupus erthematosus[J]. QJM,1996,89(7):531-538.
[50]徐风琴等 系统性红斑狼疮患者医院感染调查分析[J]广东医学1997,18(12)：838-839
[51]董敏,周厚清 降钙素原在鉴别SLE活动和合并全身性感染中的意义[J]中国热带医学2009年第9卷第8期：1469-1470
[52]汤雪彪,汪永强,袁平宗,李传达 3项检测在感染性炎症与系统性红斑狼疮中的诊断价值[J]检验医学与临床2013年12月第10卷第24期：3273-3276
[53]冷南,朱平,吴振彪,张惠琴,刘玲,杨西超 系统性红斑狼疮患者实验室检查与病情活动及感染的关系[J]西北国防医学杂志420-422
[54]张晓萍,范成明,刘秀梅 免疫抑制酸性蛋白在鉴别系统性红斑狼疮感染中的价值[J]实用全科医学2004年第2卷第5期：389-390
[55]Ayvazian LF,B adgr TL. Disseminated lupus erythematosus occuring among student nurses. N Engl J Med,1948,239:565-570
[56]鲍春德,陈晓翔.系统性红斑狼疮的治疗进展[J].现代实用医学,2008,20(11)：837.
[57]马桂琴,冯天华.中医药治疗系统性红斑狼疮之评述[J].中华实用中西医杂志。2001Vol,1(14)：469-47
[58]张峻岭,丁素先.中西医结合治疗系统性红斑狼疮经验体会[J].国现代实用医学杂志,2005年11月,4(11)：47-48
[59]宫壮,张晓良,刘必成.冬虫夏草研究现状及治疗进展[J]东南大学学报(医学版),2008,27(2)：140-144
[60]于伟,彭来君,郑慧文.虫草制剂对老年尿毒症血液透析患者血浆蛋白的影响[J].中国中西医结合肾病杂志,2002,3(8)：471-472
[61]任吉忠,闽志廉,朱有华.冬虫夏草制剂在肾移植术后早中期的应用研究[J].中国中西医结合肾病杂志,2002,3(10)581-583
[62]王苏娅,孟雪芹,陈江华等.人工培养冬虫夏草(百灵胶囊)免疫抑制作用细胞因子及可溶性细胞间黏附因子调控机制探讨[J].中国中西医结合杂志,2001,21(6)：152-153
[63]李家邦.中医学[M].6版.北京：人民卫生出版社,2006：236-237.
[64]蒋能英.试论六味地黄丸[J].中国现代医生,2008：22-23
[65]赵露,黄威,闫喜惠.应用六味地黄丸防治SLE、肾病综合征激素治疗期并发症60例临床分析[J].北华大学学报(自然科学版),2009,8：346-347
[66]曹智君,叶志中,高建华.羟氯喹联合六味地黄丸治疗系统性红斑狼疮活动合并妊娠患者疗效观察[J].《海南医学》,2012,7：12-14
[67]刘慧敏,张瑞英,姚贵申SLE患者并发院内感染220例的临床特点及易感因素分析[J]中国皮肤性病学杂志2013年10月第27卷第10期：1012-1015
[68]李秀,张风山,李洋 系统性红斑狼疮152例的临床分析[J]中华风湿科会议2008年：105
[69]许德清,陈伟雄,曾凡钦 系统性红斑狼疮与感染544例临床分析[J]临床皮肤科杂志2008年37卷第2期：72-75
[70]Lieberman LA, Tsokos GC.2010. The IL-2 defect in systemiclupus erythematosus disease has an expansive effect on hostimmunity. J Biomed Biotechnol 2010:740619.
[71]Altman A, Theofilopoulos AN, Weiner R, et al. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin2.J Exp Med 154:791-808.
[72]Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I.1991.Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352:621-624.
[73]Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E,Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H.1995. Deregulated T cell activation and autoimmunity in micelacking interleukin-2 receptor beta. Science 268:1472-1476.
[74]Malek TR, Yu A, Vincek V, Scibelli P, Kong L.2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbetadeficient mice. Implications for the nonredundant function oflL-2. Immunity 17:167-178.
[75]Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC.2001. Molecular basis of deficient IL-2 production in T cellsfrom patients with systemic lupus erythematosus. J Immuno1166:4216-4222.
[76]Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K,Kyttaris VC, Tsokos GC.2005. Systemic lupus erythematosusserum IgG increases CREM binding to the IL-2 promoter andsuppresses IL-2 production through CaMKIV. J Clin Invest115:996-1005
[77]Ichinose K, Juang YT, Crispin JC, et al. Suppression of autoimmunity and organ pathology inlupus-prone mice upon inhibition of calcium/calmodulindependent protein kinase type IV. Arthritis Rheum 63:523-529.
[78]Katsiari CG, Kyttaris VC, Juang YT, et al.Proteinphosphatase 2A is a negative regulator of IL-2 production inpatients with systemic lupus erythematosus. J Clin Invest115:3193-3204.
[79]Sunahori K, Juang YT, Kyttaris VC, Tsokos GC.2011. Promoterhypomethylation results in increased expression of proteinphosphatase 2 A in T cells from patients with systemic lupuserythematosus. J Immunol 186:4508-4517.
[80]Juang YT, Rauen T, Wang Y, et al.Transcriptional activation of the cAMPresponsive modulator promoter in human T cells is regulatedby protein phosphatase 2A-mediated dephosphorylation ofSP-1 and reflects disease activity in patients with systemiclupus erythematosus. J Biol Chem 286:1795-1801.
[81]Malek TR, Yu A, Vincek V, Scibelli P, Kong L.2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbetadeficient mice. Implications for the nonredundant function ofIL2Iit17167178
[82]La Cava A.2008. T-regulatory cells in systemic lupus erythematosus. Lupus 17:421-425.
[83]王少敏,张洁,马丽 30例女性SLE患者淋巴细胞培养上清液中IL-2、TNF-α、 IFN-γ、IL-4水平测定[J]中国妇幼保健2008年第23卷：982-983
[84]钱齐宏,张学光,殷昌硕等 系统性红斑狼疮患者外周血白介素2和白介素6及其受体的研究[J]中华皮肤科杂志2013年12月第36卷第12期：696-697
[85]宫泽砚,张峻岭 系统性红斑狼疮患者中医辨证分型与外周血IFN—丫、IL —2、xL—4、xL—10的关系研究[J] 2000全国中西医结合皮肤性病学术会议论文汇编：28-31
[86]高世明,徐星铭,魏伟,张运芳,徐叔云 系统性红斑狼疮患者外周血淋巴细胞增殖功能及其产生白细胞介素2的研究[J]中国药理学通报2000Apr；16(2)：212-213
[87]陈志强,李子仁 系统性红斑儿狼疮外周血单核细胞中IL-2及其受体mRNA的表达[J]岭南皮肤性病科杂志1998年第5卷第2期：3-5
[88]于孟学,风湿科主治医生 1053问[M]北京中国协和医科大学出版社：165-166
[89]潘延斌,李建民,刘京平等 儿童与成人系统性红斑狼疮的血沉、补体比较分析[J].广西医学,2011,33(9)：1154-1155.
[2]杜伟锋,王明艳,蔡宝昌.山茱萸炮制前后多糖对小鼠免疫功能的影响[J]·中药材,2008,31(5)：715-717.
[3]苗明三,方晓燕,杨云,等.山茱萸多糖免疫兴奋作用的研究[J].河南中医,2002,(05)：24-25.
[4]赵世萍,陈玉武,郭景珍,等.山茱萸总甙的抗炎免疫抑制作用[J].中日友好医院学报,1996,10(4)：295-298.
[5]陈涛·山茱萸水提液对骨质疏松模型小鼠骨形态学影响[J]·天津药学,2003,15(4)：5.
[6]郑素玲.山药对免疫机能低下小鼠耐缺氧能力的影响[J].动物医学进展,2010,31(2)：70-73
[7]程林,陈斌,蔡宝昌.山药多糖对2型糖尿病大鼠降糖机理的研究〔J〕.中药新药与临床药理,2006：17(2)：86-9.
[8]尹春萍,吴继洲·滓泻及其活性成分免疫调节作用研究进展(J〕·中草药,2001,32(12)：1132·
[9]刘春生,王海.药用动植物种养加工技术·牡丹皮[M].北京：中国中医药出版社,2001：77-85.
[10]王静,胡明华,董燕,等. 茯苓多糖对免疫抑制小鼠黏膜淋巴组织及脾脏中CD3+和CD19+细胞变化的影响[J]. 中国免疫学杂志,2011,27：228-231.
[11]杜标炎,李道中,王培圳.肾阳虚造型及补肾中药对大鼠免疫功能的影响[J].广州中医药大学学报,1996,13(1)：37-38.
[12]杨胜,张永祥,吕晓东,等.六味地黄汤活性部位3A的免疫调节作用机制研究[J].中国中西医结合杂志,2001,21(2)：119-120.
[13]吴军,赵凤鸣,王明艳,等. 四君子汤、六味地黄汤对环磷酰胺致小鼠免疫抑制的拮抗作用实验研究[J]. 四川中医,2007,25(10)：12-14.
[14]练颖 郑萍 官晓红 胡谦 雷丽华 陶黎 六味地黄丸对激素和免疫抑制剂治疗系统性红斑狼疮干预作用的研究[J]四川中医2006年第24卷第2期：20-21
[15]李萍,石晓宏,王风连. 六味地黄丸和地黄的免疫药理研究[J]. 中国免疫学杂志,1987,3(5)：296
[16]聂伟,张永祥,茹祥斌. 六味地黄汤免疫调节活性成分化学分离的药理学导向评价[J]. 中国中西医结合杂志,1998,18(5)：287
[17]聂伟,张永祥,茹祥斌. 六味地黄汤活性部分CA4的免疫调节作用研究[J]. 中药药理与临床,1998,14(2)：1
[18]宋艳丽,郭俐宏,朱克刚 百令胶囊对大鼠急性肾缺血再灌注损伤的保护作用[J]陕西医学杂志2014年1月第43卷第1期：25-26,37
[19]田晓,冯晓明,孟晓华,百令胶囊对环孢素A肾病大鼠免疫功能影响[J] Chinese Journal of Coal Industry Medicine sep.2013,VOL.16, NO.9:1516-1518
[20]宋艳丽,刘兴林,陈德森 百令胶囊对实验性糖尿病大鼠肾脏的保护作用[J]齐鲁医学杂志2014年2月第29卷第1期Med J Qilu, February 2014, Vol 2.9, No.1:35-37
[21]黄虹,杨丕坚,李舒敏,吕以培,黄中莹百令胶囊对Graves病患者T淋巴细胞亚群的影响[J]中国实验方剂学杂志2013年10月第19卷第20期：296-299
[22]陈丽,贾晓民,邵青 百令胶囊对尘肺患者外周血 T细胞亚群的影响及其临床意义[J]中国临床研究 2013年11月第26卷第11期：1172-1173
[23]李暖,陈新德,杨达胜,赵德安,毕凌云 百令胶囊对大鼠肾小管间质纤维化的防治作用[J]中国中西医结合肾病杂志2007年4月第8卷第4期：227-228
[24]吴艺红,王实,百令胶囊对肺心病病人免疫功能作用的研究[J]中国实验方剂学杂志1995年第1卷第1期：45-46
[25]刘宝忠,张花,杨坤,吴海燕,廖有乔 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响[J]医药导报2009年6月第28卷第6期：727-728
[26]王晓乐,邱潮林,吴秀梅等.SLE患者外周血T细胞亚群凋亡特点及其相关机制的研究[J].中国免疫学杂志,2010,26(04)：348-353.
[27]Aleocer VJ, Alarcon SD. Deereased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus[J]. J Clin Inves.1982,69:1388.
[28]Skanae T, Murkawaa Y, Suzuki N,et al. Familial occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosus[J]. Am J Med.1989,385:390.
[29]Warrington RJ, Sauder PJ, Homik J, et al. Reversible interleukin-2 response defects in system lupus erythematosus[J]. Clin ExP Immunol.1989,163:167.
[30]BounpasDT,AustinHA,VaughnEM,etal.Contolled trail of pulse methylpredisolong verse two regiments of pulse cyclophosphamide in sever lupus nephritis[J]Lancet,1992,340:741-745
[31],储萍,赵亚军,李卫党等.系统性红斑狼疮患者外周血T辅助细胞因子的表达, 江苏大学学报(医学版)杂志.2002,：12)4：335-336
[32]Aleoeer VJ,etal. Defeetive monoeyte Produetion of and T lymphocyte response to interleukin-1 in the peripheral blood of patients with SLE.Clinexp Immunol 1984;54:125.
[33]AleoeerVJ,etal.Defeetive monoeyte Produetion of and T LymPhocyte response to interleuk in the PeriPheral blood of Patients withSLE.ClinExP Immunol 1984, (5) 4:125.
[34]Frazer TH,etal.T IymPhoeyte subpopulations Defined by two sets of monoclonal antibodies in chronie active hepatitis and systemie lupus ery-thematosus. Clin Exp Immunol.1982;50:107.
[35]RapPaPortRS,Dodge GR.Prostaglandin E inhibits the produetion of human interleukin—2.J Exp Med 1982,155:943.
[36]刘亚光,尹培达IsL—R与SLE的临床表现和自身抗体的相关性,中国免疫学杂志.1994,3(10)：177
[37]杨剑辉,梁俊林,汤俊达等.环磷酞胺冲击疗法对狼疮病人白介素2受体表达的影响.前卫医药杂志.1994,(11)3：139-140
[38]彭永麟,胡建达,吕联煌.免疫性疾病患者血清可溶性白细胞介素一2受体水平.福建医学院学报,1995(24)4：321-322
[39]Wongchinsri J, Tantawichien T, OsirMi, et al Infection in Thaipatients with systemic lupus erythematosus a review of hospitalized patients.Med Assoc Tha,i 2002,85(Suppll):S34-39.
[40]RosnerS,GinzlerEM,Diamond HS,Weiner M,Schlesinger M,Fries JF,wasner C,Medsger TA Jr,Ziegler G,Klippel JH,Hadler NM,Albert DA,Hess EV,Spencer-Green G,Grayzel A,Worth D,Hahn Bh,Bernett EV.A multicenter study of outcome in systemic lupus erythematosus.2.Causes of death. Arthritis Rheum,1982,25:612-617
[41]邹晋梅,杨静,刘毅 系统性红斑狼疮感染状况及死亡原因分析[J]西部医学2011年2月第23卷第2期：356-358
[42]三森明夫 风湿病诊疗笔记[M] 北京；人民军医出版社,2013：44
[43]李海瑞 益气补肾汤治疗狼疮性肾炎气阴两虚型的临床研究[D]福建福建 中医药大学2012：1
[44]蔡小燕,许艳丽,林小军,傅君舟等 黄芪注射液对系统性红斑狼疮患者细胞凋亡和免疫功能的影响[J]中国中西医结合杂志2006年5月第26卷第5期：443-445
[45]杜彭露糖结合凝集素(MBL)在系统性红斑狼疮(SLE)及其合并感染患者血清含量的检测及意义[d]天津：天津中医科大学2010年：Ⅰ-Ⅱ
[46]Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies[J]. Curr Opin Rheumatol,2003,15(5):528-534.
[47]Ginzle E, et al.Computer analysis If factors influening frequency of infection in systemic lupus erythematosus. Arthritis Rheum,1978,21:37-44
[48]Bosch X, Guilabert A, Pallares L, et al. Infections in systemic lupus erythematosus:a prospective and controlled study of 110 patients[J]. Lupus,2006,15(9):584-589.
[49]Paton NI, Cheong IK, Kong NC, et al. Risk factor for infection in Malaysian patient with systimic Lupus erthematosus[J]. QJM,1996,89(7):531-538.
[50]徐风琴等 系统性红斑狼疮患者医院感染调查分析[J]广东医学1997,18(12)：838-839
[51]董敏,周厚清 降钙素原在鉴别SLE活动和合并全身性感染中的意义[J]中国热带医学2009年第9卷第8期：1469-1470
[52]汤雪彪,汪永强,袁平宗,李传达 3项检测在感染性炎症与系统性红斑狼疮中的诊断价值[J]检验医学与临床2013年12月第10卷第24期：3273-3276
[53]冷南,朱平,吴振彪,张惠琴,刘玲,杨西超 系统性红斑狼疮患者实验室检查与病情活动及感染的关系[J]西北国防医学杂志420-422
[54]张晓萍,范成明,刘秀梅 免疫抑制酸性蛋白在鉴别系统性红斑狼疮感染中的价值[J]实用全科医学2004年第2卷第5期：389-390
[55]Ayvazian LF,B adgr TL. Disseminated lupus erythematosus occuring among student nurses. N Engl J Med,1948,239:565-570
[56]鲍春德,陈晓翔.系统性红斑狼疮的治疗进展[J].现代实用医学,2008,20(11)：837.
[57]马桂琴,冯天华.中医药治疗系统性红斑狼疮之评述[J].中华实用中西医杂志。2001Vol,1(14)：469-47
[58]张峻岭,丁素先.中西医结合治疗系统性红斑狼疮经验体会[J].国现代实用医学杂志,2005年11月,4(11)：47-48
[59]宫壮,张晓良,刘必成.冬虫夏草研究现状及治疗进展[J]东南大学学报(医学版),2008,27(2)：140-144
[60]于伟,彭来君,郑慧文.虫草制剂对老年尿毒症血液透析患者血浆蛋白的影响[J].中国中西医结合肾病杂志,2002,3(8)：471-472
[61]任吉忠,闽志廉,朱有华.冬虫夏草制剂在肾移植术后早中期的应用研究[J].中国中西医结合肾病杂志,2002,3(10)581-583
[62]王苏娅,孟雪芹,陈江华等.人工培养冬虫夏草(百灵胶囊)免疫抑制作用细胞因子及可溶性细胞间黏附因子调控机制探讨[J].中国中西医结合杂志,2001,21(6)：152-153
[63]李家邦.中医学[M].6版.北京：人民卫生出版社,2006：236-237.
[64]蒋能英.试论六味地黄丸[J].中国现代医生,2008：22-23
[65]赵露,黄威,闫喜惠.应用六味地黄丸防治SLE、肾病综合征激素治疗期并发症60例临床分析[J].北华大学学报(自然科学版),2009,8：346-347
[66]曹智君,叶志中,高建华.羟氯喹联合六味地黄丸治疗系统性红斑狼疮活动合并妊娠患者疗效观察[J].《海南医学》,2012,7：12-14
[67]刘慧敏,张瑞英,姚贵申SLE患者并发院内感染220例的临床特点及易感因素分析[J]中国皮肤性病学杂志2013年10月第27卷第10期：1012-1015
[68]李秀,张风山,李洋 系统性红斑狼疮152例的临床分析[J]中华风湿科会议2008年：105
[69]许德清,陈伟雄,曾凡钦 系统性红斑狼疮与感染544例临床分析[J]临床皮肤科杂志2008年37卷第2期：72-75
[70]Lieberman LA, Tsokos GC.2010. The IL-2 defect in systemiclupus erythematosus disease has an expansive effect on hostimmunity. J Biomed Biotechnol 2010:740619.
[71]Altman A, Theofilopoulos AN, Weiner R, et al. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin2.J Exp Med 154:791-808.
[72]Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I.1991.Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352:621-624.
[73]Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E,Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H.1995. Deregulated T cell activation and autoimmunity in micelacking interleukin-2 receptor beta. Science 268:1472-1476.
[74]Malek TR, Yu A, Vincek V, Scibelli P, Kong L.2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbetadeficient mice. Implications for the nonredundant function oflL-2. Immunity 17:167-178.
[75]Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC.2001. Molecular basis of deficient IL-2 production in T cellsfrom patients with systemic lupus erythematosus. J Immuno1166:4216-4222.
[76]Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K,Kyttaris VC, Tsokos GC.2005. Systemic lupus erythematosusserum IgG increases CREM binding to the IL-2 promoter andsuppresses IL-2 production through CaMKIV. J Clin Invest115:996-1005
[77]Ichinose K, Juang YT, Crispin JC, et al. Suppression of autoimmunity and organ pathology inlupus-prone mice upon inhibition of calcium/calmodulindependent protein kinase type IV. Arthritis Rheum 63:523-529.
[78]Katsiari CG, Kyttaris VC, Juang YT, et al.Proteinphosphatase 2A is a negative regulator of IL-2 production inpatients with systemic lupus erythematosus. J Clin Invest115:3193-3204.
[79]Sunahori K, Juang YT, Kyttaris VC, Tsokos GC.2011. Promoterhypomethylation results in increased expression of proteinphosphatase 2 A in T cells from patients with systemic lupuserythematosus. J Immunol 186:4508-4517.
[80]Juang YT, Rauen T, Wang Y, et al.Transcriptional activation of the cAMPresponsive modulator promoter in human T cells is regulatedby protein phosphatase 2A-mediated dephosphorylation ofSP-1 and reflects disease activity in patients with systemiclupus erythematosus. J Biol Chem 286:1795-1801.
[81]Malek TR, Yu A, Vincek V, Scibelli P, Kong L.2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbetadeficient mice. Implications for the nonredundant function ofIL2Iit17167178
[82]La Cava A.2008. T-regulatory cells in systemic lupus erythematosus. Lupus 17:421-425.
[83]王少敏,张洁,马丽 30例女性SLE患者淋巴细胞培养上清液中IL-2、TNF-α、 IFN-γ、IL-4水平测定[J]中国妇幼保健2008年第23卷：982-983
[84]钱齐宏,张学光,殷昌硕等 系统性红斑狼疮患者外周血白介素2和白介素6及其受体的研究[J]中华皮肤科杂志2013年12月第36卷第12期：696-697
[85]宫泽砚,张峻岭 系统性红斑狼疮患者中医辨证分型与外周血IFN—丫、IL —2、xL—4、xL—10的关系研究[J] 2000全国中西医结合皮肤性病学术会议论文汇编：28-31
[86]高世明,徐星铭,魏伟,张运芳,徐叔云 系统性红斑狼疮患者外周血淋巴细胞增殖功能及其产生白细胞介素2的研究[J]中国药理学通报2000Apr；16(2)：212-213
[87]陈志强,李子仁 系统性红斑儿狼疮外周血单核细胞中IL-2及其受体mRNA的表达[J]岭南皮肤性病科杂志1998年第5卷第2期：3-5
[88]于孟学,风湿科主治医生 1053问[M]北京中国协和医科大学出版社：165-166
[89]潘延斌,李建民,刘京平等 儿童与成人系统性红斑狼疮的血沉、补体比较分析[J].广西医学,2011,33(9)：1154-1155.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |